2025 Q4 -tulosraportti
68 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sittenA significant bright spot Orban lost well for the EU Trump's quack quack reaches new heights Vance and his campaign also lost Vance and Trump's ridiculous love for Putin shows it all when they supported Orban Vance stay home also from Greenland This will probably be the wildest green transition. We must all be independent of fossil energy Well NVO upgrades soon
·17 t sittenHere is why Novo Nordisk (NVO) is one of the best growth stocks to buy in the next decade. Novo Nordisk (NYSE: NVO) is one of the best growth stocks to buy in the next decade. On April 2nd, Novo Nordisk announced the results from the ORION study, which is a population-adjusted indirect treatment comparison/ITC evaluating the efficacy and safety of oral semaglutide 25 mg (Wegovy pill) compared to orforglipron 36 mg. Data from the clinical trials OASIS 4 and ATTAIN-1 indicate that oral semaglutide 25 mg was associated with greater average weight loss. The comparison also showed that orforglipron 36 mg had approximately 14 times higher odds of treatment discontinuation due to gastrointestinal side effects compared to the semaglutide tablet. The study further highlighted differences in patient tolerance and noted that orforglipron was associated with ~4 times higher odds of stopping the medication due to any side effect. Although the ORION analysis adjusted for baseline characteristics such as body weight and sex, researchers noted that differences in trial protocol and low event counts should be considered when interpreting the scope of these findings. These results are scheduled to be presented at the Obesity Medicine Association's annual conference in 2026 to help healthcare professionals with clinical decision-making. Here is Why Novo Nordisk (NVO) is One of the Best Growth Stocks to Buy for the Next Decade Here is why Novo Nordisk (NVO) is one of the best growth stocks to buy in the next decade 15 states with the best healthcare in the USA Novo Nordisk (NYSE: NVO) is a pharmaceutical manufacturer for global pharmaceutical products, operating through two segments: Obesity and Diabetes Care and Rare Diseases. The company was founded in 1923 and is headquartered in Denmark. https://finance.yahoo.com/sectors/healthcare/articles/why-novo-nordisk-nvo-one-050138635.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALjxk8JAaZw4UGoCJW8aFb8705OAgTBbu1qtvXltg1WO9VONpRSnjBK9-W-gh3VmRBJ_j4-4-S5euo_vpV-7bYYBQyOvPrl0Cq7xwM2I1QqtDKmmHA8drATNCvKvUAx6O6UiI1pWIED2I7o-qhzLvZJK1duWQx9eFnYWxdCX3V31&guccounter=2
·13 t sitten · MuokattuI should have sold all novo instead of buying the dip. I no longer believe in the management and the stock. 1 year ahead. It only took 1 year to lose 75%! As soon as I run out of cash for better stocks, it's out. I am in the process of a big rotation. Ps: isn't it unwise to buy nvo adr on nyse as a Dane, compared to Danish novo b?
·20 t sittenit will be interesting how much it falls tomorrow ⬇️⬇️⬇️
15 t sitten15 t sittenOil related and defense will rise - everything else will drop 📉
·1 päivä sittenNovo Nordisk is approaching the upper end of its sales forecast Major bank UBS now assesses that Novo Nordisk is moving towards the best half of its own sales forecast for the year. This occurs ahead of the company's upcoming quarterly report, which is expected on May 6, 2026. Key points from the analysis Positive outlook: - UBS expects a milder view on this year's sales development than previously assumed. Wegovy success in the USA: - The positive assessment is largely due to a promising development in the number of prescriptions issued for the weight-loss drug Wegovy in the American market. New forms: - The analysis points to growth for the product both in injection form and as a pill. Recommendation and price target: - Despite the positive trends, UBS reiterates a "neutral" recommendation for the Novo share, with a price target of 332 kr. Source: - Article from Finans / MarketWire: "Novo Nordisk nærmer sig bedste halvdel af sin salgsprognose, vurderer UBS" (published April 10, 2026).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
68 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenA significant bright spot Orban lost well for the EU Trump's quack quack reaches new heights Vance and his campaign also lost Vance and Trump's ridiculous love for Putin shows it all when they supported Orban Vance stay home also from Greenland This will probably be the wildest green transition. We must all be independent of fossil energy Well NVO upgrades soon
- ·17 t sittenHere is why Novo Nordisk (NVO) is one of the best growth stocks to buy in the next decade. Novo Nordisk (NYSE: NVO) is one of the best growth stocks to buy in the next decade. On April 2nd, Novo Nordisk announced the results from the ORION study, which is a population-adjusted indirect treatment comparison/ITC evaluating the efficacy and safety of oral semaglutide 25 mg (Wegovy pill) compared to orforglipron 36 mg. Data from the clinical trials OASIS 4 and ATTAIN-1 indicate that oral semaglutide 25 mg was associated with greater average weight loss. The comparison also showed that orforglipron 36 mg had approximately 14 times higher odds of treatment discontinuation due to gastrointestinal side effects compared to the semaglutide tablet. The study further highlighted differences in patient tolerance and noted that orforglipron was associated with ~4 times higher odds of stopping the medication due to any side effect. Although the ORION analysis adjusted for baseline characteristics such as body weight and sex, researchers noted that differences in trial protocol and low event counts should be considered when interpreting the scope of these findings. These results are scheduled to be presented at the Obesity Medicine Association's annual conference in 2026 to help healthcare professionals with clinical decision-making. Here is Why Novo Nordisk (NVO) is One of the Best Growth Stocks to Buy for the Next Decade Here is why Novo Nordisk (NVO) is one of the best growth stocks to buy in the next decade 15 states with the best healthcare in the USA Novo Nordisk (NYSE: NVO) is a pharmaceutical manufacturer for global pharmaceutical products, operating through two segments: Obesity and Diabetes Care and Rare Diseases. The company was founded in 1923 and is headquartered in Denmark. https://finance.yahoo.com/sectors/healthcare/articles/why-novo-nordisk-nvo-one-050138635.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALjxk8JAaZw4UGoCJW8aFb8705OAgTBbu1qtvXltg1WO9VONpRSnjBK9-W-gh3VmRBJ_j4-4-S5euo_vpV-7bYYBQyOvPrl0Cq7xwM2I1QqtDKmmHA8drATNCvKvUAx6O6UiI1pWIED2I7o-qhzLvZJK1duWQx9eFnYWxdCX3V31&guccounter=2·13 t sitten · MuokattuI should have sold all novo instead of buying the dip. I no longer believe in the management and the stock. 1 year ahead. It only took 1 year to lose 75%! As soon as I run out of cash for better stocks, it's out. I am in the process of a big rotation. Ps: isn't it unwise to buy nvo adr on nyse as a Dane, compared to Danish novo b?
- ·20 t sittenit will be interesting how much it falls tomorrow ⬇️⬇️⬇️15 t sitten15 t sittenOil related and defense will rise - everything else will drop 📉
- ·1 päivä sittenNovo Nordisk is approaching the upper end of its sales forecast Major bank UBS now assesses that Novo Nordisk is moving towards the best half of its own sales forecast for the year. This occurs ahead of the company's upcoming quarterly report, which is expected on May 6, 2026. Key points from the analysis Positive outlook: - UBS expects a milder view on this year's sales development than previously assumed. Wegovy success in the USA: - The positive assessment is largely due to a promising development in the number of prescriptions issued for the weight-loss drug Wegovy in the American market. New forms: - The analysis points to growth for the product both in injection form and as a pill. Recommendation and price target: - Despite the positive trends, UBS reiterates a "neutral" recommendation for the Novo share, with a price target of 332 kr. Source: - Article from Finans / MarketWire: "Novo Nordisk nærmer sig bedste halvdel af sin salgsprognose, vurderer UBS" (published April 10, 2026).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
68 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenA significant bright spot Orban lost well for the EU Trump's quack quack reaches new heights Vance and his campaign also lost Vance and Trump's ridiculous love for Putin shows it all when they supported Orban Vance stay home also from Greenland This will probably be the wildest green transition. We must all be independent of fossil energy Well NVO upgrades soon
- ·17 t sittenHere is why Novo Nordisk (NVO) is one of the best growth stocks to buy in the next decade. Novo Nordisk (NYSE: NVO) is one of the best growth stocks to buy in the next decade. On April 2nd, Novo Nordisk announced the results from the ORION study, which is a population-adjusted indirect treatment comparison/ITC evaluating the efficacy and safety of oral semaglutide 25 mg (Wegovy pill) compared to orforglipron 36 mg. Data from the clinical trials OASIS 4 and ATTAIN-1 indicate that oral semaglutide 25 mg was associated with greater average weight loss. The comparison also showed that orforglipron 36 mg had approximately 14 times higher odds of treatment discontinuation due to gastrointestinal side effects compared to the semaglutide tablet. The study further highlighted differences in patient tolerance and noted that orforglipron was associated with ~4 times higher odds of stopping the medication due to any side effect. Although the ORION analysis adjusted for baseline characteristics such as body weight and sex, researchers noted that differences in trial protocol and low event counts should be considered when interpreting the scope of these findings. These results are scheduled to be presented at the Obesity Medicine Association's annual conference in 2026 to help healthcare professionals with clinical decision-making. Here is Why Novo Nordisk (NVO) is One of the Best Growth Stocks to Buy for the Next Decade Here is why Novo Nordisk (NVO) is one of the best growth stocks to buy in the next decade 15 states with the best healthcare in the USA Novo Nordisk (NYSE: NVO) is a pharmaceutical manufacturer for global pharmaceutical products, operating through two segments: Obesity and Diabetes Care and Rare Diseases. The company was founded in 1923 and is headquartered in Denmark. https://finance.yahoo.com/sectors/healthcare/articles/why-novo-nordisk-nvo-one-050138635.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALjxk8JAaZw4UGoCJW8aFb8705OAgTBbu1qtvXltg1WO9VONpRSnjBK9-W-gh3VmRBJ_j4-4-S5euo_vpV-7bYYBQyOvPrl0Cq7xwM2I1QqtDKmmHA8drATNCvKvUAx6O6UiI1pWIED2I7o-qhzLvZJK1duWQx9eFnYWxdCX3V31&guccounter=2·13 t sitten · MuokattuI should have sold all novo instead of buying the dip. I no longer believe in the management and the stock. 1 year ahead. It only took 1 year to lose 75%! As soon as I run out of cash for better stocks, it's out. I am in the process of a big rotation. Ps: isn't it unwise to buy nvo adr on nyse as a Dane, compared to Danish novo b?
- ·20 t sittenit will be interesting how much it falls tomorrow ⬇️⬇️⬇️15 t sitten15 t sittenOil related and defense will rise - everything else will drop 📉
- ·1 päivä sittenNovo Nordisk is approaching the upper end of its sales forecast Major bank UBS now assesses that Novo Nordisk is moving towards the best half of its own sales forecast for the year. This occurs ahead of the company's upcoming quarterly report, which is expected on May 6, 2026. Key points from the analysis Positive outlook: - UBS expects a milder view on this year's sales development than previously assumed. Wegovy success in the USA: - The positive assessment is largely due to a promising development in the number of prescriptions issued for the weight-loss drug Wegovy in the American market. New forms: - The analysis points to growth for the product both in injection form and as a pill. Recommendation and price target: - Despite the positive trends, UBS reiterates a "neutral" recommendation for the Novo share, with a price target of 332 kr. Source: - Article from Finans / MarketWire: "Novo Nordisk nærmer sig bedste halvdel af sin salgsprognose, vurderer UBS" (published April 10, 2026).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt